Although extra-renal expression of SGLT-2 was described in various tissues, the expression of SGLT-2 in human hepatocytes still remains unclear [27], in contrast with GLP-1RA, with known beneficial effects on NAFLD/NASH that are partly mediated by hepatocyte GLP-1 receptors [28]. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatotic liver disease.